151 results about "Diabetic rat" patented technology

The present invention provides an antioxidative composition with high safety, which is capable of lessening oxidative stress due to active oxygen species, free radicals, or the like in vivo, thereby preventing the occurrence or worsening of a disease. It was confirmed that by using a composition containing oxidized coenzyme Q and/or reduced coenzyme Q, the amount of urinary 8-hydroxydeoxyquanosine can be decreased in normal or diabetic animals. Also, in histopathological research of the spleens of diabetic rats, it was confirmed that spleen tissue denaturation caused by oxidative stress can be prevented. It was thus found that oxidative stress in vivo can be lessened. According to the present invention, oxidative stress in vivo can be lessened by using a composition containing coenzyme Q as an active ingredient.

The invention discloses a hydrogel dressing containing a recombinant human epidermal growth factor. The hydrogel dressing consists of 100 volume parts of mixed solution A and 2 to 8 volume parts of cross-linking agent; the mixed solution A is prepared by mixing 2.0 to 5.0 mass percent of polyvinyl alcohol aqueous solution and 0.5 to 2.0 mass percent of sodium alginate aqueous solution according to the mass ratio of (2-5): 1, and adding 0 to 0.1 mass percent of sodium benzoate, 5 to 20ug/g of recombinant human epidermal growth factor and 2.0 to 10 mass percent of glycerol; and the gel dressing is prepared by taking the 2 to 8 volume parts of cross-linking agent prepared by mixing sodium borate solution and calcium chloride solution, dripping the cross-linking agent into the 100 volume parts of mixed solution A, standing and defoaming to obtain the gel dressing. The dressing has good biocompatibility and mild and simple preparation condition, can be formed at room temperature, can effectively keep the activity of the recombinant epidermal growth factor and has controlled release effect on the recombinant epidermal growth factor. The dressing has good effect of treating the wound of rats suffering from diabetes mellitus, and can accelerate healing of the wound.

A feungreek extract containing the common saponin of feungreek for preventing and treating diabetes and its chronic complications is prepared through extracting with alcohol, macroreticular adsorption, washing for removing impurities, eluting, concentrating the eluting liquid, and drying.

The invention discloses a moringa leaf extract with blood sugar lowering activity and a preparation method thereof. The preparation method comprises the following steps: crushing and sieving, performing alkali treatment, performing protease enzymolysis, performing cellulase enzymolysis, performing high-pressure homogenization, performing high-temperature extraction, performing low-temperature high-speed centrifugation, performing ultrafiltration separation and concentration, performing protease enzymolysis, performing low-temperature high-speed centrifugation, performing secondary ultrafiltration separation and concentration, performing freeze drying and the like to obtain the moringa leaf extract with the blood sugar lowering activity. The extract has the polysaccharide content of 30% orabove; an animal experimental model of a type-2 diabetic rat verifies that the extract has good blood sugar lowering activity and can effectively reduce the fasting blood glucose of the type-2 diabetic rat and enhance the oral glucose tolerance dosage thereof; the acting effect of the extract is similar to that of metformin with the same dosage. An extracting technology is simple, the whole technological process can meet a food-grade requirement, and the moringa leaf extract can be applied to the field of medicines, health-care products, food and the like.

The present invention provides a transdermal administration kit, wherein the transdermal administration kit comprises a microneedle array and a transdermal administration patch; the penetration depth of the microneedle array into the skin is about 20 to 150 um; the transdermal administration patch comprises a medicament holder and insulin as active medicament components; the medicament holder is made from inert substances capable of adsorbing and holding the adsorbed liquid. The transdermal administration kit provided by the invention enables the blood sugar value of a rat suffering from diabetes mellitus to be kept constant during a period of from 2 to 24 hours after the rat is administered the formulation. So the transdermal administration kit provided by the invention can replace the hypodermic injection of protamine zinc insulin and other similar ways to maintain the stabilization of the basic insulin level in the human body blood.

The invention discloses health-care vinegar, a brewing method and hyperglycemic reduction application thereof. The health-care vinegar is prepared from 4 to 7 parts of rice, and 2 to 4 parts of yam. The brewing method comprises the following steps: (1) pulping the rice and yam with water, regulating the starch concentration to be over 10 percent by adopting sterile water or traditional Chinese medicinal extract, and heating the mixture for 5 to 10 minutes at the temperature of between 125 and 130 DEG C; (2) adding rhizopus, activated dried yeast, aroma-producing yeast and lactic acid bacteria into the sterilized mixture to ferment distilled wort, adding lactic acid bacteria seed fermentation broth into the mixture when the alcohol content is detected to be between 6 and 8 percent, leading the fermentation temperature to be between 26 and 34 DEG C, adding edible salt into the mixture when the acidity of the fermentation broth is not changed, and stopping alcoholic fermentation; and (3) ageing the fermented acid solution for over 15 days at the temperature of between 12 and 20 DEG C, and filtering the solution to obtain the health-care vinegar. The brewed health-care vinegar can reduce blood sugar of experimental II type diabetic rats, shows certain dose-response relationship, can improve the insulin sensitivity of the experimental II type diabetic rats, can improve the carbohydrate tolerance of the experimental II type diabetic rats, and improve the content of hepatic glycogen and muscle glycogen.

The present invention discloses the pH-sensitive nanoparticles composed of pH-sensitive polymer, hydrophobic material, internal stabilizer, external stabilizer content and insulin drug. The present invention also includes a method for preparation of pH-sensitive nanoparticles, in particular, a multiple emulsions solvent evaporation method. The pH-sensitive nanoparticles of the present invention show good pH-sensitive property with 100-300 nanometer particle size. Significant decrease in blood glucose level is observed in streptozotocin (STZ)-induced diabetic rats and the bioavailability of insulin is more than 10% after oral administration of the insulin-loaded pH-sensitive nanoparticles.

The invention discloses a Guangxi rubus suavissimus antidiabetic potential marker metabolic pathway based on the metabonomics and a research method, which relates to a research method for a natural plant medicine action mechanism. The invention aims at solving the problems that the existing single pharmacology method cannot systematically and comprehensively evaluate the action mechanism of the natural plant medicine. The method comprises the following steps: (1) detecting and analyzing a urine metabolite of a diabetic rat after being induced by streptozotocin and intervened by rubus suavissimus; (2) selecting nine rubus suavissimus antidiabetic related urine potential markers, and identifying the potential markers; and (3) selecting six metabolic pathways of the rubus suavissimus for resisting the diabetics, and analyzing. By adopting the Guangxi rubus suavissimus antidiabetic potential marker metabolic pathway and the research method, the antidiabetic action mechanism of the rubus suavissimus can be more comprehensively, efficiently, rapidly and integrally evaluated without deviation, and evidence can be provided for the description and further development of the national medicine action mechanism.

The invention discloses a lactobacillus plantarum with dual blood glucose-reducing target and an application thereof. The lactobacillus plantarum ST-2 with dual blood glucose-reducing target and higher restraining activity is acquired by screening in the manners of in vitro inhibitory activity, probiotic property determination and principal component analysis; the inhibition ratio of the CFS extract thereof for alpha-glucosaccharase activity is 13.44%; the inhibition ratio for dipeptidyl peptidase-IV activity is 21.525%. An experiment proves that ST-2 has a certain inhibitory activity for differently sourced alpha-glucosaccharase and dipeptidyl peptidase-IV; the carbonylated hemoglobin value of type-II diabetic rat is obviously reduced, so that ST-2 has ultrahigh application value for delaying the carbohydrate absorption of the diabetic after the meal and reducing postprandial blood sugar increasing; ST-2 is prepared into freeze-drying bacteria powder in high viable count; the viable count is as high as 89% of that before freeze-drying; besides, ST-2 has an excellent fermenting effect; the application of ST-2 in producing dairy products or being added as a food ingredient into functional food has excellent preventing and intervening effects for diabetes and obesity.

The invention relates to a marine oligosaccharide compound with type II diabetes resisting activity, which is a compound which is formed by following steps: taking D-polymannose aldehydic oligosaccharide which comes from sea and contains carboxyl in each oligosaccharide ring, reacting with dilute alkali and chromium salt solution and introducing trivalent chromium ions which is closely relative tothe generation and the development of diabetes into oligosaccharide molecules. A pharmacological experiment proves that the product has remarkable effect on accelerating insulin secretion, is not influenced by amylin and has effects on lightening glucose load, improving blood-lipoid metabolism, insulin sensitivity and certain kidney protection and lightening pancreatic injury for type II diabetesrats and mouse. The product of the invention comes from marine natural species, has the advantages of good security, unique structure, low molecular weight, high chromium binding ratio, good oral absorption effect, and the like, can play a hypoglycemic role in a plurality of links and has favorable market application prospect on the aspect of preventing and treating type II diabetes.

The invention discloses application of dendrobium stem alkaloids in preparation of medicament for treating diabetes mellitus and a product. The dendrobium stem alkaloids are components of lipotropismtotal alkaloids, which are extracted from dendrobium stems. Compared with the prior art, the invention further defines the pharmacologic action and the pharmacologic mechanism of the treatment of thediabetes mellitus through researching the influences of the dendrobium stem alkaloids to a mice blood sugar raising model and a high blood sugar and high blood fat chained streptozotocin induced diabetes mellitus rat model which are caused by epinephrine, and provides a pharmacology basis for the development of dendrobium stem medicinal materials.

The invention discloses a taxus chinensis extractive with blood sugar reduction effect. The taxus chinensis extractive is extracted from taxus chinensis plant branches and leaves by using modern separation methods. The content of refined biflavone in an effective part can be 50-80%; the main effective components are umbrella pine biflavone, ginkgetin, isoginkgetin, ginkgetin biflavone and amentoflavon. Experimental research shows that the taxus chinensis extractive can not only remarkably suppress the alpha-glucosidase activity, but also has an outstanding effect of reducing the rat blood sugar of diabetes, can relieve or suppress happening and development of diabetic complication, and has the hope to be developed into novel blood sugar reduction medicines.

The invention discloses application of TTR (transthyretin) to angiogenesis inhibition, and belongs to the fields of biochemistry, molecular biology and medicine. After the TTR is given to mammals, inSTZ induced diabetes rat and mouse models, the new vessels of eyes are obviously reduced. Tumor new vessel, diabetes new vessel, eye new vessel and brain new vessel in vitro experiment models verify that the TTR has the effect of inhibiting the angiogenesis; the result shows that the TTR can act on an in vitro cell model in anoxic environment of brain and can continuously and efficiently inhibit the generation of new vessels. When the TTR acts on endothelial cells of umbilical veins, the formation of 90 percent of vessels can be obviously inhibited; when the TTR acts on endothelial cells of cerebral microvessel, the formation of 95 percent of vessels can be effectively inhibited; when the TTR acts on the endothelial cells of eye microvessel, the formation of 90 percent of vessels can be effectively inhibited; when the TTR acts on rat and mouse models, the as high as generation of 90 percent of new vessels can be effectively inhibited.

The invention discloses application of transthyretin (TTR) to the inhibition of ocular neovascularization and belongs to the field of biochemistry, molecular biology and medical science. The application finds out that mammal TTR is given and ocular new blood vessels in STZ (Streptozocin)-induced diabetes mellitus rat and mouse models are obviously reduced. An in-vivo experiment model of ocular neovascularization and brain neovascularization verifies that the TTR has the effect of inhibiting the neovascularization and a result shows that the TTR acts on ocular capillary endothelial cells and can be used for effectively inhibiting the formation of 90 percent of the blood vessels; and when the TTR acts in the rat and mouse models, high up to 90% of neovascularization can be effectively inhibited.

The invention belongs to the technical field of new indications of drugs, and particularly discloses an application of externally used skin generation oil in preparation of drugs for preventing or treating diabetic peripheral circulation disturbance and foot ulcer. The externally used skin generation oil can effectively improve low temperature at soles due to peripheral circulation disturbance in early stage of diabetic foot ulcer, recover the sole pain threshold to a normal level, accelerate diabetic foot ulcer wound repair and shorten the wound repair time. The area of a foot ulcer wound surface of a diabetic rat is reduced to (4.0 plus or minus 0.1 mm<2>) from (51.3 plus or minus 3.5 mm<2>) after treated with the skin generation oil for 35 days, the wound surface heals basically, the skin is red and dry, and the skin surface is smooth; HE (hematoxylin-eosin) dyeing results show that the skin tissue structures of the foot wound surfaces of rats in an externally used skin generation oil group and an externally used skin generation oil and metformin group is relatively complete, collagen fibers at the wound edge are arranged in order, and inflammatory cell infiltration of wound surface tissue is reduced obviously.

The invention discloses a traditional Chinese medicine composition for treating diabetes ulcer and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is the traditional Chinese medicine composition for external use. The traditional Chinese medicine composition is prepared by a conventional method comprising the following steps of compounding traditional Chinese medicine raw materials of Chinese angelica, angelica dahurica, lithospermum and licorice roots in a certain proportion, extracting and refining the compounded traditional Chinese medicine raw materials and adding preparation adjuvants. Experiments prove that the traditional Chinese medicine composition provided by the invention can obviously increase the heal rate of diabetes rat ulcer and obviously improve the pathology structure of the diabetes rat ulcer, and the mechanism of the traditional Chinese medicine composition is relevant to the improvement on expression quantity ofInsulin-Like growth factor -1 receptors,epidermal growth factors andalkaline fibrocyte forming growth factorsinnew granulation tissues at the ulcer. The invention provides an effective treatment medicine for external use for treating the diabetes ulcer.

The present invention is directed to methods for improving glycemic control in humans and animals comprising the step of administering a composition comprising an amino acid content including 4-hydroxyisoleucine in an amount between about 60% and about 70% of a total weight of the amino acid content, together with one or more amino acids selected from the group consisting of glutamate, aspartate, arginine, cysteine, threonine, serine, glycine, alanine, valine, methionine, isoleucine, and histidine (inclusive of any chemical salts, anhydrides, or isomers of any of the foregoing), in addition to, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Fasting blood glucose and glucose tolerance were studied in normal human subjects, in human subjects diagnosed with Metabolic Syndrome X, and in diabetic rats by means of dosing the subjects with compositions comprising 4-hydroxyisoleucine in an amount between about 20% and about 30% of the total weight of the composition, wherein improving glycemic control in standard glucose tolerance tests.

The invention discloses that dioscin has certain inhibition activity to rat lens AR, has certain delaying function to both galactose cataract and diabetic cataract, and can obviously reduce content of albumin in diabetic rat urine. So that the dioscin can prevent, delay and/or treat diabetic complications, particularly diseases, such as sugar cataract, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and the like.

The invention relates to an artificial insulinogen analogue gene, while it adds the internal stay sequence of KDEL to accumulate the protein in the internal network to avoid degrading enzyme of cell. And it uses GPD of high level epiphyte to start the target gene and arranged in the carrier transformed with lucid ganoderma; uses electric hitting method or agricillin or PEG medium gene method to transform lucid ganoderma; the ELISA test has proved that the content of artificial insulinogen analogue is 105.0 mug/g-174.8 mug/g of the fresh weight, and at 4.40%-10.40% of soluble protein. And the invention can effectively reduce blood sugar.

Disclosed is a method for preparing insulin oral formulation which comprises, (1) dissolving acrylic resin III in anhydrous alcohol solution, obtaining solution A, (2) charging insulin into the solution A to obtain solution B, (3) dissolving sodium taurocholate in liquid paraffin, charging into solution B to obtain solution C, (4) dissolving gelatin into distilled water, charging into solution C to obtain a first enveloped insulin microballoons, which is called solution D, (5) charging equal amount of fluid wax with solution C into solution D to obtain solution E, (6) dissolving acetylsalicylic acid into distilled water to form miscible liquid, charging equal amount of miscible liquid of gelatin and distilled water into another solution A, charging into solution E, finally obtaining a second enveloped insulin microballoon solution.

The invention belongs to the technical field of traditional Chinese medicines, relates to a traditional Chinese medicinal composition and a preparation method thereof, and particularly relates to a traditional Chinese medicinal composition for treating diabetes mellitus and a preparation method thereof. Against existing technical defects, the traditional Chinese medicinal composition for treating or preventing diabetes mellitus comprises the following components in parts by weight: 10-20 parts radices trichosanthis, 5-20 parts of raw rehmmania root, 5-15 parts of astragalus membranaceus, 5-15 parts of kudzu vine root, 1-10 parts of dendrobium nobile, 9-15 parts of schisandra chinensis, 5-15 parts of salvia miltiorrhiza, 1.5-9 parts of radix ophiopogonis, 9-15 parts of poria and 5.5-15 parts of liquorice. The traditional Chinese medicinal composition can be used for remarkably improving symptoms of diabetes mellitus in the aspects of blood glucose, microalbuminuria and glycosylated hemoglobin of a diabetes rat.

Accelerated formation of advanced glycation/lipoxidation end products (AGEs/ALEs) has been implicated in the pathogenesis of various diabetic complications. Several natural and synthetic compounds have been proposed and tested as inhibitors of AGE/ALE formation. We have previously reported the therapeutic effects of several new AGE/ALE inhibitors on the prevention of nephropathy and dyslipidemia in streptozotocin (STZ)-induced diabetic rats. In this study, we investigated the effects of various concentrations of LR-90 on the progression of renal disease and its effects on AGE and receptor for AGE (RAGE) protein expression on the kidneys of diabetic STZ-rats. In vitro studies were also performed to determine if LR-90 could inhibit the expression of various pro-inflammatory mediators in human monocytic cells.